Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus adt in patients with metastatic hormone-sensitive prostate cancer

Orion corporation press release 16 september 2024 at 11.30 eest          darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus adt in patients with metastatic hormone-sensitive prostate cancer results from the pivotal phase iii aranote trial evaluating darolutamide plus androgen deprivation therapy (adt) showed a statistically significant increase in radiological progression-free survival (rpfs) compared to placebo plus adt in patients with metastatic hormone-sensitive prostate cancer darolutamide plus adt now has positive data both with and without docetaxel based on two pivotal phase iii studies in metastatic hormone-sensitive prostate cancer safety analysis reconfirms the established tolerability profile of darolutamide as observed in the aramis and arasens trials data from aranote trial presented as a late-breaking oral presentation at the esmo 2024 congress and simultaneously published in the journal of clinical oncology abstract: lba68 results from the phase iii aranote trial have shown that darolutamide plus androgen deprivation therapy (adt) significantly reduced the risk of radiological progression or death by 46% compared to placebo plus adt (hr 0.54; 95% ci 0.41–0.71; p
ADT Ratings Summary
ADT Quant Ranking